<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00773357</url>
  </required_header>
  <id_info>
    <org_study_id>0808004163</org_study_id>
    <secondary_id>RL1DA024857</secondary_id>
    <secondary_id>P50DA033945</secondary_id>
    <nct_id>NCT00773357</nct_id>
  </id_info>
  <brief_title>Modeling Stress-precipitated Smoking Behavior for Medication Development</brief_title>
  <official_title>Modeling Stress-precipitated Smoking Behavior for Medication Development</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Research on Women's Health (ORWH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether guanfacine or carvedilol will attenuate the
      ability of stress to precipitate smoking lapse behavior in treatment seeking and
      non-treatment seeking daily smokers. Participants seeking treatment for smoking will
      participate in a smoking cessation attempt after the laboratory sessions. Also looking at
      gender differences.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>latency to initiate ad-lib smoking session</measure>
    <time_frame>during the laboratory sessions</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of cigarettes smoking during the ad-lib period</measure>
    <time_frame>during the laboratory sessions</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>success rates in smoking cessation attempt</measure>
    <time_frame>during smoking cessation attempt</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gender differences in medication effects</measure>
    <time_frame>lab session and smoking cessation attempt</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>Guanfacine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>guanfacine 3mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carvedilol 50 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>guanfacine</intervention_name>
    <description>3 mg/day, with 3-week lead-in medication period. The starting dose is 0.5 mg/day for days 1-3, followed by 1.5mg/day for days 4-7, followed by 2 mg/day for days 8-12, followed by 2.5 mg/day for days 13-15, followed by 3 mg/day from day 16 to remainder of study. 5-day taper at end of study.</description>
    <arm_group_label>Guanfacine</arm_group_label>
    <other_name>Tenex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>50 mg/day titrated to stead state. The starting dose is 12.5 mg/day for day 1, followed by 25 mg/day for days 2-3, followed by 50 mg from days 4 to the end of the study.</description>
    <arm_group_label>Carvedilol</arm_group_label>
    <other_name>Coreg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ages 18-60

          -  able to read and write in English

          -  smokers

        Exclusion Criteria:

          -  any significant current medical conditions that would contraindicate smoking

          -  current DSM-IV abuse or dependence of other substances, other than nicotine (or
             caffeine) dependence

          -  positive test result at intake appointments on urine drug screens conducted for
             opiates, cocaine, or benzodiazepines

          -  women who are pregnant or nursing

          -  suicidal, homicidal or evidence of severe mental illness

          -  participants prescribed any psychotropic drug in the 30 days prior to study enrollment

          -  blood donation within the past 6 weeks

          -  participants who have engaged in a quit attempt in the past 3 months

          -  specific exclusions for administration of guanfacine/carvedilol not already specified
             include: Hypotensive individuals with sitting blood pressure below 90/50 mmHG; EKG
             evidence at baseline screening of any clinically significant conduction abnormalities,
             including a Bazlett's QTc &gt;450 msec for men and QTc&gt;470 msec for women; known
             intolerance for guanfacine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherry A McKee, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale Center for Clinical Investigation, Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2008</study_first_submitted>
  <study_first_submitted_qc>October 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2008</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>smoking lapse behavior</keyword>
  <keyword>smoking cessation</keyword>
  <keyword>guanfacine</keyword>
  <keyword>carvedilol</keyword>
  <keyword>medication effect on smoking lapse behavior</keyword>
  <keyword>medication effect on smoking cessation</keyword>
  <keyword>stress</keyword>
  <keyword>gender differences</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Guanfacine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

